Last $48.99 USD
Change Today -0.16 / -0.33%
Volume 4.4K
NVZMY On Other Exchanges
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

novozymes a/s-unspons adr (NVZMY) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/3/14 - $51.11
52 Week Low
10/16/14 - $38.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

novozymes a/s-unspons adr (NVZMY) Related Businessweek News

No Related Businessweek News Found

novozymes a/s-unspons adr (NVZMY) Details

Novozymes A/S produces and sells industrial enzymes, microorganisms, and biopolymers worldwide. The company offers solutions for the agriculture industry, including enzymes to enhance digestibility and nutritional value of animal feed; microbial solutions to maintain water quality, limit risks of disease, and enhance yields in aquaculture; and microbial-based biofertility, biocontrol, and bioyield enhancer products to naturally produce healthier crops and enhance yields. It also provides a portfolio of enzymes for application in biofuel production; recombinant products and technologies to the medical device and drug delivery market; and food and beverages enzymes for applications in baking, brewing, dairy, distilling, flavor enhancement, food specialties, health and nutrition, juice, meat processing, oils and fats, starch, and wine industries. In addition, the company offers household care enzyme and microbial agents for use in cleaning solutions, dishwashing, and laundry; enzymes for biopreparation, degreasing, and re-bating of leather; enzymes for pulp and paper production processes, such as bleach boosting, deinking, drainage enhancement, effluent control, pitch control, refining, slime control, starch modification, and stickies control; enzymatic solutions for processing textiles; and microbial solutions for biological wastewater treatment. Novozymes A/S has a strategic alliance with Monsanto Company to discover, develop, and sell microbial solutions for farmers. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

6,079 Employees
Last Reported Date: 01/20/15
Founded in 1925

novozymes a/s-unspons adr (NVZMY) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr9.7M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: kr5.9M
Executive Vice President of Business Operatio...
Total Annual Compensation: kr5.4M
Executive Vice President of Research & Develo...
Total Annual Compensation: kr6.0M
Executive Vice President of Supply Operations
Total Annual Compensation: kr5.9M
Compensation as of Fiscal Year 2014.

novozymes a/s-unspons adr (NVZMY) Key Developments

Novozymes A/S Approves Dividend for 2014

Novozymes A/S approved the dividend of DKK 3.00 per share of DKK 2 for 2014, an increase of 20% compared with 2013 at the Annual Shareholders' Meeting held on February 25, 2015.

Novozymes A/S Presents at Bank of America Merrill Lynch Global Agriculture Conference 2015, Feb-25-2015

Novozymes A/S Presents at Bank of America Merrill Lynch Global Agriculture Conference 2015, Feb-25-2015 . Venue: Fort Lauderdale, Florida, United States.

Novozymes A/S Reports Audited Consolidated and Parent Earnings Results for the Year Ended December 31, 2014; Provides Consolidated Earnings Guidance for 2015

Novozymes A/S reported audited consolidated and parent earnings results for the year ended December 31, 2014. On consolidated basis, revenue was DKK 12,459 million against DKK 11,746 million last year. EBITDA was DKK 4,400 million against DKK 3,639 million last year. Operating profit/EBIT was DKK 3,384 million against DKK 2,901 million last year. Net profit attributable to shareholders of Novozymes A/S was DKK 2,526 million against DKK 2,200 million last year. Cash flow from operating activities was DKK 4,525 million against DKK 2,599 million last year. Purchases of property, plant and equipment was DKK 703 million against DKK 762 million last year. Return on equity was 22.6% against 21.3% last year. Diluted earnings per share were DKK 8.02 against DKK 6.93 last year. Exchange rates had a negative impact on sales, and sales in LCY were up by 7%. Organically, sales also grew by 7%. Sales to the Bioenergy industry were the most significant contributor to sales growth. The higher operating cash flow was mainly a result of The BioAg Alliance agreement, a favorable development in net working capital and higher net profit. The deferred income received through The BioAg Alliance is recognized as a liability and impacts operating cash flow as a positive change in net working capital. Profit before tax was DKK 3,279 million against DKK 2,759 million last year. Purchase of intangible assets was DKK 20 million against DKK 24 million last year. For 2014, on parent basis, revenue was DKK 6,991 million against DKK 6,484 million last year. Operating profit/EBIT was DKK 2,464 million against DKK 2,020 million last year. Profit before tax was DKK 2,990 million against DKK 2,659 million last year. Net profit was DKK 2,451 million against DKK 2,145 million last year. For 2015, the consolidated company expects sales growth in the range of 13% - 15%, organic sales growth in the range of 7% - 9%, EBIT growth in the range of 12% - 14%, EBIT margin growth in the range of 26% - 27%, net investments excluding acquisitions of DKK ~1,000 million, free cash flow before acquisitions in the range of DKK 2,500 million - DKK 2,700 million. The company expects good underlying sales growth and similarly high profitability in 2015, even with increasing investments in R&D and business development. Higher sales and a positive contribution from currencies are expected to drive the strong EBIT growth and more than offset the negative impact from the absence of the one-time net gain from The BioAg Alliance and other one-time items realized in 2014, expected lower other operating income, and an expected cost expansion in R&D, and sales and business development. The effective tax rate is expected to be 22% - 23%. Net profit is expected to grow by 10% -12%, driven by growth in EBIT, which is expected to be offset slightly by higher net financial costs caused by the recent surge in the USD, which will lead to a loss on forward currency contracts.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVZMY:US $48.99 USD -0.16

NVZMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Chr Hansen Holding A/S kr298.80 DKK +1.00
Ebro Foods SA €17.04 EUR +0.22
EMS-Chemie Holding AG SFr.419.00 CHF +1.50
Kerry Group PLC €65.00 EUR +0.14
Sensient Technologies Corp $63.61 USD +0.08
View Industry Companies

Industry Analysis


Industry Average

Valuation NVZMY Industry Range
Price/Earnings 37.2x
Price/Sales 7.4x
Price/Book 8.2x
Price/Cash Flow 31.4x
TEV/Sales 6.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVOZYMES A/S-UNSPONS ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at